Literature DB >> 21944677

Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials).

Peter Damman1, Lene Holmvang, Jan G P Tijssen, Bo Lagerqvist, Tim C Clayton, Stuart J Pocock, Fons Windhausen, Alexander Hirsch, Keith A A Fox, Lars Wallentin, Robbert J de Winter.   

Abstract

The aim of this study was to evaluate the independent prognostic value of qualitative and quantitative admission electrocardiographic (ECG) analysis regarding long-term outcomes after non-ST-segment elevation acute coronary syndromes (NSTE-ACS). From the Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II), Invasive Versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS), and Randomized Intervention Trial of Unstable Angina 3 (RITA-3) patient-pooled database, 5,420 patients with NSTE-ACS with qualitative ECG data, of whom 2,901 had quantitative data, were included in this analysis. The main outcome was 5-year cardiovascular death or myocardial infarction. Hazard ratios (HRs) were calculated with Cox regression models, and adjustments were made for established outcome predictors. The additional discriminative value was assessed with the category-less net reclassification improvement and integrated discrimination improvement indexes. In the 5,420 patients, the presence of ST-segment depression (≥1 mm; adjusted HR 1.43, 95% confidence interval [CI] 1.25 to 1.63) and left bundle branch block (adjusted HR 1.64, 95% CI 1.18 to 2.28) were independently associated with long-term cardiovascular death or myocardial infarction. Risk increases were short and long term. On quantitative ECG analysis, cumulative ST-segment depression (≥5 mm; adjusted HR 1.34, 95% CI 1.05 to 1.70), the presence of left bundle branch block (adjusted HR 2.15, 95% CI 1.36 to 3.40) or ≥6 leads with inverse T waves (adjusted HR 1.22, 95% CI 0.97 to 1.55) was independently associated with long-term outcomes. No interaction was observed with treatment strategy. No improvements in net reclassification improvement and integrated discrimination improvement were observed after the addition of quantitative characteristics to a model including qualitative characteristics. In conclusion, in the FRISC II, ICTUS, and RITA-3 NSTE-ACS patient-pooled data set, admission ECG characteristics provided long-term prognostic value for cardiovascular death or myocardial infarction. Quantitative ECG characteristics provided no incremental discrimination compared to qualitative data.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21944677     DOI: 10.1016/j.amjcard.2011.08.002

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Differences in negative T waves among acute coronary syndrome, acute pulmonary embolism, and Takotsubo cardiomyopathy.

Authors:  Masami Kosuge; Toshiaki Ebina; Kiyoshi Hibi; Kengo Tsukahara; Noriaki Iwahashi; Masaomi Gohbara; Yasushi Matsuzawa; Kozo Okada; Satoshi Morita; Satoshi Umemura; Kazuo Kimura
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

2.  Comparative clinical implications of admission electrocardiographic findings for patients with non-ST-segment elevation myocardial infarction.

Authors:  Eun-Sun Jin; Chang-Bum Park; Dong-Hee Kim; Hui-Jeong Hwang; Jin-Man Cho; Il Suk Sohn; Chong-Jin Kim
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

3.  Prognostic value of admission electrocardiographic findings in non-ST-segment elevation myocardial infarction.

Authors:  Peng-Fei Chen; Liang Tang; Jun-Yu Pei; Jun-Lin Yi; Zhen-Hua Xing; Zhen-Fei Fang; Sheng-Hua Zhou; Xin-Qun Hu
Journal:  Clin Cardiol       Date:  2020-03-03       Impact factor: 2.882

4.  Machine Learning Improves Risk Stratification After Acute Coronary Syndrome.

Authors:  Paul D Myers; Benjamin M Scirica; Collin M Stultz
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.